Tenax Therapeutics (TENX) Net Income towards Common Stockholders: 2011-2024
Historic Net Income towards Common Stockholders for Tenax Therapeutics (TENX) over the last 11 years, with Dec 2024 value amounting to -$17.6 million.
- Tenax Therapeutics' Net Income towards Common Stockholders rose 379.72% to $33.9 million in Q4 2016 from the same period last year, while for Dec 2016 it was $11.5 million, marking a year-over-year decrease of 88.67%. This contributed to the annual value of -$17.6 million for FY2024, which is 126.43% down from last year.
- Latest data reveals that Tenax Therapeutics reported Net Income towards Common Stockholders of -$17.6 million as of FY2024, which was down 126.43% from -$7.8 million recorded in FY2023.
- In the past 5 years, Tenax Therapeutics' Net Income towards Common Stockholders registered a high of $11.0 million during FY2022, and its lowest value of -$17.6 million during FY2024.
- In the last 3 years, Tenax Therapeutics' Net Income towards Common Stockholders had a median value of -$7.8 million in 2023 and averaged -$4.8 million.
- Data for Tenax Therapeutics' Net Income towards Common Stockholders shows a maximum YoY plummeted of 170.36% (in 2023) over the last 5 years.
- Tenax Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$9.9 million in 2020, then reached $11.0 million in 2022, then plummeted by 170.36% to -$7.8 million in 2023, then crashed by 126.43% to -$17.6 million in 2024.